Cargando…

L-DOPA in Parkinson’s Disease: Looking at the “False” Neurotransmitters and Their Meaning

L-3,4-dihydroxyphenylalanine (L-DOPA) has been successfully used in the treatment of Parkinson’s disease (PD) for more than 50 years. It fulfilled the criteria to cross the blood–brain barrier and counteract the biochemical defect of dopamine (DA). It remarkably worked after some adjustments in line...

Descripción completa

Detalles Bibliográficos
Autores principales:	Chagraoui, Abdeslam, Boulain, Marie, Juvin, Laurent, Anouar, Youssef, Barrière, Grégory, De Deurwaerdère, Philippe
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	MDPI 2019
Materias:	Review
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6981630/ https://www.ncbi.nlm.nih.gov/pubmed/31906250 http://dx.doi.org/10.3390/ijms21010294

Ejemplares similares

Limiting Monoamines Degradation Increases L-DOPA Pro-Locomotor Action in Newborn Rats
por: Khsime, Inès, et al.
Publicado: (2023)

Neurobiological and Pharmacological Perspectives of D3 Receptors in Parkinson’s Disease
por: Chagraoui, Abdeslam, et al.
Publicado: (2022)

Dopamine D3 Receptor: Contemporary Views of Its Function and Pharmacology for Neuropsychiatric Diseases
por: De Deurwaerdère, Philippe, et al.
Publicado: (2021)

Effect of the 5-HT(2C) Receptor Agonist WAY-163909 on Serotonin and Dopamine Metabolism across the Rat Brain: A Quantitative and Qualitative Neurochemical Study
por: Whitestone, Sara, et al.
Publicado: (2019)

Imbalanced Dopaminergic Transmission Mediated by Serotonergic Neurons in L-DOPA-Induced Dyskinesia
por: Navailles, Sylvia, et al.
Publicado: (2012)

Editorial: Contemporary Perspective on 5-HT(2C) Receptor Function and Its Pharmacological Targeting
por: De Deurwaerdère, Philippe, et al.
Publicado: (2020)

Impairment of Serotonergic Transmission by the Antiparkinsonian Drug L-DOPA: Mechanisms and Clinical Implications
por: Miguelez, Cristina, et al.
Publicado: (2017)

L-dopa-induced dyskinesia: beyond an excessive dopamine tone in the striatum
por: Porras, Gregory, et al.
Publicado: (2014)

Editorial: New GPCR targets and modulators to treat CNS disorders
por: De Deurwaerdère, Philippe, et al.
Publicado: (2022)

Interactions Between the Serotonergic and Other Neurotransmitter Systems in the Basal Ganglia: Role in Parkinson’s Disease and Adverse Effects of L-DOPA
por: Muñoz, Ana, et al.
Publicado: (2020)

Chronic Administration of Fipronil Heterogeneously Alters the Neurochemistry of Monoaminergic Systems in the Rat Brain
por: Bharatiya, Rahul, et al.
Publicado: (2020)

Lorcaserin Alters Serotonin and Noradrenaline Tissue Content and Their Interaction With Dopamine in the Rat Brain
por: Di Giovanni, Giuseppe, et al.
Publicado: (2020)

L-DOPA-therapy in Parkinson’s disease: some personal reflections on L-DOPA therapy from Vienna and Berlin
por: Riederer, Peter, et al.
Publicado: (2023)

Molecular Effects of L-dopa Therapy in Parkinson’s Disease
por: Dorszewska, Jolanta, et al.
Publicado: (2014)

Beyond L-DOPA: hope for Parkinson’s treatment and diagnosis
Publicado: (2017)

A Subset of Purposeless Oral Movements Triggered by Dopaminergic Agonists Is Modulated by 5-HT(2C) Receptors in Rats: Implication of the Subthalamic Nucleus
por: Lagière, Mélanie, et al.
Publicado: (2020)

Inhaling xenon ameliorates l‐dopa‐induced dyskinesia in experimental parkinsonism
por: Baufreton, Jérôme, et al.
Publicado: (2018)

L-DOPA
por: Hornykiewicz, Oleh
Publicado: (2017)

Parkinson’s disease, L-DOPA, and endogenous morphine: A revisit
por: Stefano, George B., et al.
Publicado: (2012)

The acute and long‐term L‐DOPA effects are independent from changes in the activity of dorsal raphe serotonergic neurons in 6‐OHDA lesioned rats
por: Miguelez, C, et al.
Publicado: (2016)

Altered cerebellar connectivity in Parkinson's patients ON and OFF L-DOPA medication
por: Festini, Sara B., et al.
Publicado: (2015)

The Design and Evaluation of an l-Dopa–Lazabemide Prodrug for the Treatment of Parkinson’s Disease
por: Hoon, Monique, et al.
Publicado: (2017)

Receptor Ligands as Helping Hands to L-DOPA in the Treatment of Parkinson’s Disease
por: Bello, Fabio Del, et al.
Publicado: (2019)

An Integrative Approach to Treat Parkinson's Disease: Ukgansan Complements L-Dopa by Ameliorating Dopaminergic Neuronal Damage and L-Dopa-Induced Dyskinesia in Mice
por: Huh, Eugene, et al.
Publicado: (2019)

L-Dopa and Behavior
por: Kebabian, John
Publicado: (1974)

Cannabinoid 1/2 Receptor Activation Induces Strain-Dependent Behavioral and Neurochemical Changes in Genetic Absence Epilepsy Rats From Strasbourg and Non-epileptic Control Rats
por: De Deurwaerdère, Philippe, et al.
Publicado: (2022)

Neurogenic mechanisms for locomotor-respiratory coordination in mammals
por: Juvin, Laurent, et al.
Publicado: (2022)

Readiness Potential in Parkinson's Disease: Effects of L-Dopa Therapy and Brain Transplants
por: Martínez, D. N. Velázquez, et al.
Publicado: (1992)

The role of GRK6 in animal models of Parkinson's Disease and L-DOPA treatment
por: Managò, Francesca, et al.
Publicado: (2012)

L-DOPA-Induced Dyskinesia in a Genetic Drosophila Model of Parkinson’s Disease
por: Blosser, Joshua A., et al.
Publicado: (2020)

Individual Magnetoencephalography Response Profiles to Short-Duration L-Dopa in Parkinson’s Disease
por: Peña, Edgar, et al.
Publicado: (2021)

Selenoprotein T Exerts an Essential Oxidoreductase Activity That Protects Dopaminergic Neurons in Mouse Models of Parkinson's Disease
por: Boukhzar, Loubna, et al.
Publicado: (2016)

Novel anti-apoptotic L-DOPA precursors SuperDopa and SuperDopamide as potential neuroprotective agents for halting/delaying progression of Parkinson’s disease
por: Wiesen, Tom, et al.
Publicado: (2022)

L-Dopa and the Albino Riddle: Content of L-Dopa in the Developing Retina of Pigmented and Albino Mice
por: Roffler-Tarlov, Suzanne, et al.
Publicado: (2013)

Monoaminergic control of spinal locomotor networks in SOD1(G93A) newborn mice
por: Milan, Léa, et al.
Publicado: (2014)

Polymorphisms of Dopamine Receptor Genes and Risk of L-Dopa–Induced Dyskinesia in Parkinson’s Disease
por: Comi, Cristoforo, et al.
Publicado: (2017)

L-dopa treatment increases oscillatory power in the motor cortex of Parkinson's disease patients
por: Cao, Chunyan, et al.
Publicado: (2020)

l-DOPA and Its Receptor GPR143: Implications for Pathogenesis and Therapy in Parkinson’s Disease
por: Goshima, Yoshio, et al.
Publicado: (2019)

Dopamine D3 Receptor Plasticity in Parkinson’s Disease and L-DOPA-Induced Dyskinesia
por: Lanza, Kathryn, et al.
Publicado: (2021)

Radiation-induced Brain Calcification Leads to L-dopa-resistant Parkinsonism and Cerebellar Ataxia
por: Shimada, Tomoyo, et al.
Publicado: (2022)

Cannot write session to /tmp/vufind_sessions/sess_00fdfkuiiemb96m7fnb19i45q8